Send to:

Choose Destination
See comment in PubMed Commons below
Vaccine. 2010 Aug 31;28(38):6256-64. doi: 10.1016/j.vaccine.2010.07.004. Epub 2010 Jul 16.

A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor.

Author information

  • 1Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Sandtorstr. 1, 39106 Magdeburg, Germany.


An adherently growing MDCK cell line was adapted in a two-step process in a fully defined medium and in suspension. The resulting MDCK.SUS2 cells were subsequently evaluated for their potential as host cells for influenza vaccine production in two lab-scale bioreactors (wave and stirred-tank). Cell concentrations up to 2.3 x 10(6)cells/mL were obtained after 96 h, which is slightly higher than cell concentrations obtained with adherent MDCK cells cultivated on microcarriers (2g/L). Infections with influenza A/PR/8/34 and B/Malaysia resulted in high virus titers (2.90 and 2.75 log HA units/100 microL, respectively). The monitoring of extracellular metabolites, including amino acids, revealed a change in some of the metabolite consumption or release profiles, which indicates changes in metabolism during the adaptation process. Overall, the MDCK.SUS2 cell line represents a new cell substrate for a robust influenza vaccine production in a fully defined process.

(c) 2010 Elsevier Ltd. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk